Kimberley S. Mak, MD, MPH
Assistant Professor
Boston University School of Medicine
Dept of Radiation Oncology

MD, Harvard Medical School
MPH, Harvard School of Public Health




Kimberley S. Mak, MD, MPH, is an Assistant Professor of Radiation Oncology at the Boston University School of Medicine and its affiliate Boston Medical Center. She received her MPH from Harvard School of Public Health (2014), MD from Harvard Medical School (2010) and AB summa cum laude in Biochemical Sciences from Harvard College (2005). Dr. Mak completed an internship in Internal Medicine at Brigham and Women's Hospital (2011), followed by residency in the Harvard Radiation Oncology Program (2015), training at Massachusetts General Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Children's Hospital of Boston, and Boston Medical Center. Dr. Mak has board certification in Radiation Oncology by the American Board of Radiology. She speaks English and Cantonese. Her specialties include thoracic, gastrointestinal, breast, and musculoskeletal malignancies. She leads the Cyberknife® radiosurgery program for thoracic and gastrointestinal malignancies.

Her research interests include patient-reported outcomes including quality of life; disparity outcomes research; translational research; intensity-modulated and image-guided radiotherapy; CyberKnife® stereotactic radiotherapy; and functional imaging in radiotherapy. She has training and experience in biostatistics, epidemiology, decision analysis, meta-analysis, clinical trial design, and molecular and cell biology laboratory work.

Boston Medical Center



2008-2009 Howard Hughes Medical Institute: Medical Student Research Training Fellowship
2005 Harvard College: Phi Beta Kappa
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Yan SX, Qureshi MM, Dyer M, Truong MT, Mak KS. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer. Lung Cancer. 2019 May; 131:147-153.View Related Profiles. PMID: 31027693.
     
  2. Sridhar P, Bhatt M, Qureshi MM, Asokan S, Truong MT, Suzuki K, Mak KS, Litle VR. Esophageal Cancer Presentation, Treatment, and Outcomes Vary With Hospital Safety-Net Burden. Ann Thorac Surg. 2019 May; 107(5):1472-1479.View Related Profiles. PMID: 30605641.
     
  3. Yan SX, Qureshi MM, Suzuki K, Dyer M, Truong MT, Litle V, Mak KS. Definitive treatment patterns and survival in stage II non-small cell lung cancer. Lung Cancer. 2018 10; 124:135-142.View Related Profiles. PMID: 30268452.
     
  4. Mak KS, Lee SW, Balboni TA, Marcus KJ. Clinical outcomes and toxicity following palliative radiotherapy for childhood cancers. Pediatr Blood Cancer. 2018 Jan; 65(1). PMID: 28853208.
     
  5. Giacalone NJ, Qureshi MM, Mak KS, Kirke D, Patel SA, Shah BA, Salama AR, Jalisi S, Truong MT. Adjuvant chemoradiation does not improve survival in elderly patients with high-risk resected head and neck cancer. Laryngoscope. 2018 04; 128(4):831-840.View Related Profiles. PMID: 28833217.
     
  6. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017 Jun 01; 3(6):827-831. PMID: 27892978; DOI: 10.1001/jamaoncol.2016.3834;.
     
  7. Yan SX, Qureshi MM, Truong MT, Mak KS. Patterns of Care and Survival Outcomes in Stage II Non-Small Cell Lung Cancer: An Analysis of the National Cancer Database. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):251. PMID: 28587045.
     
  8. Mak KS, Agarwal A, Qureshi MM, Truong MT. Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database. Cancer Med. 2017 Jun; 6(6):1192-1200.View Related Profiles. PMID: 28440040.
     
  9. Patel SA, Qureshi MM, Mak KS, Sahni D, Giacalone NJ, Ezzat W, Jalisi S, Truong MT. Impact of total radiotherapy dose on survival for head and neck Merkel cell carcinoma after resection. Head Neck. 2017 Jul; 39(7):1371-1377.View Related Profiles. PMID: 28370725; DOI: 10.1002/hed.24776;.
     
  10. Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Chen RC, Shipley WU, Milowsky MI, Efstathiou JA. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016 Dec 01; 96(5):1028-1036. PMID: 27727064; DOI: 10.1016/j.ijrobp.2016.08.023;.
     
Showing 10 of 23 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 23 publications over 9 distinct years, with a maximum of 6 publications in 2017

YearPublications
20051
20081
20102
20143
20152
20165
20176
20182
20191

Mentorship for students interested in oncology, radiation oncology, lung cancer, gastrointestinal cancer, gynecologic cancers, patient-reported outcomes including quality of life, disparities outcomes research, and outcomes research.

Available to Mentor as: (Review Mentor Role Definitions):
  • Career Mentor
  • Project Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')


Recent (within 3 months)

Higher Radiation Doses Tied To Increased Longevity In Node-Negative Lung Cancer

Reuters Health via M.D./alert 4/30/2019

818 Harrison Ave
Boston MA 02118
Google Map


Mak's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department